Narlaprevir

Narlaprevir is an azabicyclohexane, specifically (1R,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane, substituted at positions 2S and 3 with [(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]aminoacyl and N-({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)-3-methyl-L-valyl groups, respectively. It is a hepatitis C virus (HCV) NS3/4A serine protease inhibitor (Ki = 6 nM) used in the treatment of chronic hepatitis C. It functions as a hepatitis C protease inhibitor, antiviral drug, EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor, and anticoronaviral agent. It is classified as a sulfone, urea, tertiary carboxamide, azabicyclohexane, pyrrolidinecarboxamide, secondary carboxamide, and member of cyclopropanes.